Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Activity Reduction vs Advice for Plantar Hotspots in Diabetes (MONITOR)

18. september 2026 opdateret af: Saima Abass Tahammal, Shifa International Hospital

Objectively Monitored Individualized Activity Reduction Versus Standard Advice for Resolution of Plantar Thermal Hotspots in Adults With Diabetes: A Randomized Controlled Trial

This randomized proof-of-concept trial will evaluate whether an individualized, objectively monitored temporary reduction in walking activity can accelerate resolution of plantar thermal hotspots in adults with diabetes who are at high risk of foot ulceration. A plantar thermal hotspot is defined as a temperature difference greater than 2.2°C between corresponding sites on the two feet on two consecutive days.

Participants with a confirmed eligible hotspot will be randomly assigned to either an individualized numerical daily step-count target or standard non-quantified advice to reduce walking and weight-bearing activity. Both groups will receive standard diabetic-foot preventive care, daily foot-temperature monitoring, and objective activity monitoring.

The primary outcome is the time from randomization to sustained resolution of the index plantar thermal hotspot during the first 14 days. Participants will be followed for 28 days to assess hotspot recurrence, foot-related outcomes, safety, and acceptability.

Studieoversigt

Detaljeret beskrivelse

This is a prospective, multicenter, randomized, parallel-group, controlled proof-of-concept trial in adults with diabetes at high risk of diabetic foot ulceration.

Potential participants will undergo standardized bilateral plantar temperature assessment. A confirmed plantar thermal hotspot is defined as an inter-foot temperature difference greater than 2.2°C at the same anatomically comparable plantar site on two consecutive daily measurements. Only participants with a confirmed hotspot, intact skin at the index site, and no foot condition requiring immediate therapeutic treatment or offloading will enter the randomized trial.

Eligible participants will be randomized 1:1 to individualized, objectively monitored activity reduction or standard non-quantified activity-reduction advice. Both groups will receive guideline-concordant diabetic-foot preventive care, daily visual foot inspection, continued use of prescribed protective footwear, daily plantar-temperature monitoring, and objective step-count recording.

Participants assigned to the individualized activity-reduction group will ordinarily receive a temporary daily step-count target of no more than 50% of their objectively recorded habitual daily activity. When a 50% reduction is judged clinically inappropriate, a prespecified modified target requiring at least a 25% reduction may be used. Participants will receive feedback on their recorded activity relative to the prescribed target.

Participants assigned to the comparator group will receive standardized verbal and written advice to substantially reduce unnecessary walking and weight-bearing activity while the hotspot remains present, but they will not receive an individualized numerical step target or structured feedback comparing their activity with a prescribed target.

The primary outcome is time to uncomplicated sustained resolution of the index plantar thermal hotspot through Day 14. Sustained resolution is defined as an inter-foot temperature difference of 2.2°C or less at the index site on two consecutive valid daily measurements. Development before resolution of a clinically important foot complication requiring treatment will be considered failure to achieve uncomplicated resolution during the primary outcome period.

Participants will continue follow-up through Day 28 for assessment of hotspot recurrence, temperature-monitoring adherence, foot-related clinical outcomes, safety, and acceptability.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

100

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Punjab Province
      • Lahore, Punjab Province, Pakistan

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 80 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Age ≥18 years.
  • Type 1 or type 2 diabetes mellitus.
  • Loss of protective sensation demonstrated by standardized 10-g monofilament testing.
  • IWGDF risk category 3.
  • Previous diabetic foot ulceration and/or lower-extremity amputation consistent with IWGDF risk category 3.
  • Any previous ulcer on the relevant foot completely epithelialized and clinically healed for at least 4 weeks.
  • Confirmed plantar thermal hotspot, defined as an inter-foot temperature difference >2.2°C at the same anatomically comparable plantar site on two consecutive days.
  • Intact skin at the index hotspot.
  • Community ambulatory.
  • Able to perform daily foot-temperature measurements independently or with caregiver assistance.
  • Able to reduce ambulatory activity temporarily if assigned to the experimental intervention.
  • At least five valid days of objectively recorded daily step-count data during Days -21 through -3 relative to the first positive thermal screening measurement.
  • Objective historical activity data available from a smartphone, smartwatch, activity tracker, pedometer with stored daily counts, or another verifiable device-based source.
  • Willing to continue objective activity measurement during randomized follow-up whenever technically possible.
  • Able to provide informed consent and complete study procedures.

Exclusion Criteria:

  • Active diabetic foot ulcer or other open foot wound.
  • Blister, hemorrhagic callus, skin breakdown, or another pre-ulcerative lesion requiring immediate therapeutic management.
  • Active or suspected Charcot neuro-osteoarthropathy.
  • Clinical evidence of foot infection.
  • Critical limb-threatening ischaemia or another vascular condition requiring urgent management.
  • Recent acute foot trauma or surgery that could independently alter local foot temperature.
  • Predominantly non-ambulatory or wheelchair-dependent status.
  • Medical condition for which substantial temporary reduction in ambulatory activity would be unsafe.
  • Inability to provide the required pre-hotspot objective activity history.
  • Cognitive or functional impairment preventing study procedures without suitable caregiver assistance.
  • Absence of an anatomically valid contralateral comparison site for the proposed index hotspot.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Individualized Objectively Monitored Activity Reduction

Participants will receive standard diabetic-foot preventive care, daily plantar-temperature monitoring, and objective step-count recording, plus an individualized temporary daily step-count target. The default target will be no more than 50% of the participant's objectively recorded habitual daily activity. If a 50% reduction is judged clinically inappropriate, a prespecified modified target requiring at least a 25% reduction may be used. Participants will receive feedback comparing their recorded activity with the prescribed target and will continue the temporary activity restriction until sustained hotspot resolution.

An individualized temporary ambulatory-activity prescription initiated after confirmation of a plantar thermal hotspot. The default daily step-count target is no more than 50% of the participant's objectively recorded habitual daily activity. If a 50% reduction is judged clinically inappropriate, a prespecified modified target requiring at least a 25% reduction may be used. Participants receive objective activity monitoring and feedback comparing actual daily steps with the prescribed target until sustained hotspot resolution.

Aktiv komparator: Standard Activity-Reduction Advice

Participants will receive the same standard diabetic-foot preventive care, daily plantar-temperature monitoring, and objective step-count recording as the experimental group. They will receive standardized written and verbal advice to substantially reduce unnecessary walking and weight-bearing activity while the hotspot remains present. They will not receive an individualized numerical step-count target, percentage activity target, structured feedback comparing actual activity with a target, or escalation of the activity prescription solely because a numerical target was not achieved.

Standardized written and verbal advice to substantially reduce unnecessary walking and weight-bearing activity while the plantar thermal hotspot remains present. Participants do not receive an individualized numerical step-count target, percentage activity target, structured feedback comparing actual activity with a prescribed target, or escalation of the activity prescription based solely on failure to meet a numerical target. Objective step counts are recorded for study assessment.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Time to Uncomplicated Sustained Resolution of the Index Plantar Thermal Hotspot
Tidsramme: Randomization through Day 14

Number of days from randomization until the first of two consecutive valid daily measurements showing an inter-foot temperature difference ≤2.2°C at the index plantar site. Development before resolution of diabetic foot ulceration, a pre-ulcerative lesion requiring therapeutic offloading, infection, suspected Charcot neuro-osteoarthropathy, or another foot complication requiring treatment that supersedes the randomized strategy will be considered failure to achieve uncomplicated resolution during the primary outcome period.

Randomization through Day 14

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Proportion of Participants With Sustained Hotspot Resolution by Day 7
Tidsramme: Randomization through Day 7

Proportion of randomized participants achieving uncomplicated sustained resolution of the index plantar thermal hotspot by Day 7. Sustained resolution requires an inter-foot temperature difference ≤2.2°C at the index site on two consecutive valid daily measurements without a preceding disqualifying foot complication.

Randomization through Day 7
Percentage Change in Daily Step Count From Habitual Activity
Tidsramme: Historical baseline through Day 4

Percentage change in mean daily step count during Days 1 through 4 after randomization relative to the participant's habitual activity level. Habitual activity is defined as the median daily step count from at least five valid days during Days -21 through -3 relative to the first positive thermal screening measurement.

Historical baseline through Day 4
Cumulative Index-Site Temperature-Asymmetry Burden
Tidsramme: Randomization through Day 14

Area under the curve of the daily absolute inter-foot temperature difference at the index plantar hotspot during the 14-day primary outcome period. Daily temperature differences are calculated from corresponding bilateral plantar temperature measurements.

Randomization through Day 14
Proportion of Participants With Index-Hotspot Recurrence
Tidsramme: From sustained hotspot resolution through Day 28

Proportion of participants who develop a newly confirmed plantar thermal hotspot at the index site after achieving sustained resolution. Recurrence is defined using the prespecified hotspot criterion of an inter-foot temperature difference >2.2°C at the index site on two consecutive daily measurements.

From sustained hotspot resolution through Day 28

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Nadia Hussain, MD, PhD, Al Ain University

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. oktober 2026

Primær færdiggørelse (Anslået)

1. april 2027

Studieafslutning (Anslået)

28. april 2027

Datoer for studieregistrering

Først indsendt

18. september 2026

Først indsendt, der opfyldte QC-kriterier

18. september 2026

Først opslået (Faktiske)

25. september 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

25. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

18. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

De-identified individual participant data underlying the results reported in the primary publication will be made available, together with a data dictionary, subject to applicable ethics approval, participant consent, institutional policy, and data-protection requirements.

IPD-delingstidsramme

Beginning 12 months after publication of the primary study results and available for 5 years.

IPD-delingsadgangskriterier

Data will be made available to qualified researchers who submit a methodologically sound research proposal. Requests will be reviewed by the study investigators and, where required, the sponsoring institution. Approved data will be provided for the purposes described in the approved proposal and subject to an appropriate data-use agreement.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP
  • ANALYTIC_CODE

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner